Skip to main content
. 2022 Feb 24;8(1):5. doi: 10.1038/s41537-021-00192-x

Table 3.

Recommendations for LAI antipsychotics in the treatment of schizophrenia.

Guideline Use for a first- episode schizophrenia Use for maintenance treatment Use for nonadherence Use based on patient preference
APA, 202117 Not reported Not reported Yes Yes
Florida Medicaid Program, 202018 Yes Yes Yes Yes
BAP, 202033 No Yes Yes Yes
Oregon Health Authority, 201919 Not reported Yes Yes Yes
PPA, 201937,38 Not reported Not reported Yes Not reported
AACP, 201729 Not reported Yes Yes Yes
CPA, 201714 Not reported Not reported Not reported Yes
UNHCR, 201723 Not reported Not reported Yes Not reported
WFSBP, 201224, 201325, 201726 Not reported Yes Not reported Not reported
RANZCP, 201639 Yes Yes Yes Yes
NICE, 201434 No Yes Yes Yes
AFPBN, 201340 Yes Yes Not reported Yes
CINP, 201322 Not reported Not reported Yes Not reported
SIGN, 201335 No Yes Yes Yes
Singapore Ministry of Health, 201136 No Yes Yes Yes
Schizophrenia PORT, 201030,31 No Yes Not reported Yes
Italian Guidelines, 200841 NA NA NA NA
TMAP, 200828 Yes Yes Yes Not reported
NJDMHS, 200532 Yes Yes Yes Not reported

AACP American Association of Community Psychiatrists, AFPBN Association Française de Psychiatrie Biologique et Neuropsychopharmacologie, APA American Psychiatric Association, BAP British Association of Psychopharmacology, CINP International College of Neuropsychopharmacology, CPA Canadian Psychiatric Association, LAI long-acting injectable, no not recommended, NA not applicable, NICE National Institute for Health and Care Excellence, NJDMHS New Jersey Division of Mental Health Services, PPA Polish Psychiatric Association, PORT Patient Outcomes Research Team, RANZCP Royal Australian/New Zealand College of Psychiatrists, SIGN Scottish Intercollegiate Guidelines Network, TMAP Texas Medication Algorithm Project, UNHCR United Nations High Commissioner for Refugees, WFSBP World Federation of Societies of Biological Psychiatry, yes recommended.